-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
A phase II clinical trial Axicabtagene ciloleucel as first-line therapy in high-risk large B-cell lymphoma: the phase 2 ZUMA-12 trial published in Nature Medicine shows that early initiation of axicabtagene ciloleucel (axi-cel) treatment can Activated a complete response in 78% of 37 high-risk large B-cell lymphoma (LBCL) patients
.
axi-cel is a CAR-T immunotherapy that specifically targets the surface protein CD19 of cancerous B cells
.
The findings suggest that this type of CAR-T cell therapy -- which has shown a better safety profile -- may be more clinically beneficial than general use when used early for treatment
.
LBCL is a blood cancer characterized by mutations in specific genes and/or a range of different clinical features
.
Patients with high-risk LBCL generally respond poorly to the standard initial rounds of chemoimmunotherapy
.
axi-cel is a type of CAR-T cell therapy in which a patient's own immune cells (in this case, T cells) are modified in the laboratory to better recognize and fight cancer cells
.
axi-cel, which targets the surface protein CD 19 expressed by cancerous B cells, has been approved for use in patients with advanced B-cell lymphomas
.
However, its potential as an initial therapy in high-risk LBCL patients has been under investigation
.
Sattva Neelapu of the University of Texas MD Anderson Cancer Center and colleagues used axi-cel as initial therapy in 40 adults with high-risk LBCL (median age 61; 68% men) in a phase II trial
.
This is a single-arm clinical trial, meaning that all study subjects received the treatment
.
Of the 37 patients included in the efficacy analysis, 78% achieved a complete response -- the trial's primary outcome
.
At the time of data cut-off—median follow-up was 15.
9 months—the median duration of response, progression-free survival, and event-free survival had not yet been reached
.
Adverse safety events were consistent with previous reports of axi-cel therapy
.
These results support the researchers to further test the role of CAR-T cells targeting CD-19 in the early stages of disease treatment
.
However, large randomized trials are still needed to conduct direct comparisons with standard chemoimmunotherapy
.
Association of CAR-T cell levels in blood and serum cytokines with adverse safety events
.
Source: Neelapu et al.
©NatureNature Medicine | doi: 10.
1038/s41591-022-01731-4
.
axi-cel is a CAR-T immunotherapy that specifically targets the surface protein CD19 of cancerous B cells
.
The findings suggest that this type of CAR-T cell therapy -- which has shown a better safety profile -- may be more clinically beneficial than general use when used early for treatment
.
LBCL is a blood cancer characterized by mutations in specific genes and/or a range of different clinical features
.
Patients with high-risk LBCL generally respond poorly to the standard initial rounds of chemoimmunotherapy
.
axi-cel is a type of CAR-T cell therapy in which a patient's own immune cells (in this case, T cells) are modified in the laboratory to better recognize and fight cancer cells
.
axi-cel, which targets the surface protein CD 19 expressed by cancerous B cells, has been approved for use in patients with advanced B-cell lymphomas
.
However, its potential as an initial therapy in high-risk LBCL patients has been under investigation
.
Sattva Neelapu of the University of Texas MD Anderson Cancer Center and colleagues used axi-cel as initial therapy in 40 adults with high-risk LBCL (median age 61; 68% men) in a phase II trial
.
This is a single-arm clinical trial, meaning that all study subjects received the treatment
.
Of the 37 patients included in the efficacy analysis, 78% achieved a complete response -- the trial's primary outcome
.
At the time of data cut-off—median follow-up was 15.
9 months—the median duration of response, progression-free survival, and event-free survival had not yet been reached
.
Adverse safety events were consistent with previous reports of axi-cel therapy
.
These results support the researchers to further test the role of CAR-T cells targeting CD-19 in the early stages of disease treatment
.
However, large randomized trials are still needed to conduct direct comparisons with standard chemoimmunotherapy
.
Association of CAR-T cell levels in blood and serum cytokines with adverse safety events
.
Source: Neelapu et al.
©NatureNature Medicine | doi: 10.
1038/s41591-022-01731-4
